| Cancer type |
Sample size |
Promoter methylation |
References |
| Liver cancer |
32
42
48
60
39
42 |
62% (20/32)
79% (33/42)
67% (32/48)
62% (37/60)
56% (22/39)
45% (20/42) |
[4-11] |
| Neuroblastoma |
33 |
<10% |
[12] |
| Breast cancer |
25 |
44% (11/25) |
[4] |
| Colorectal cancer |
38 |
16% (6/38) (high-level MSI) |
[13] |
| Ovarian cancer |
89
69 |
22% (20/89)
7% (5/69) |
[14,15] |
| Gastric cancer |
75
45
30 |
67% (50/75)
69% (31/45)
37% (11/30) |
[16-18] |
| Prostate cancer |
47
101 |
43% (20/47)
31% (31/101) |
[19,20] |
| Thyroid cancer |
19 |
100% (19/19) |
[21] |
| Cervical cancer |
40 |
38% (14/40) |
[22] |
| Parathyroid cancer |
47 |
36% (17/37) |
[23] |
| Malignant pheochromocytoma |
4 |
50% (2/4) |
[23] |
| Nasopharyngeal carcinoma |
30
53 |
60% (18/30)
57% (30/53) |
[24,25] |
| Acute lymphoblastic leukemia |
71
72 |
16% (T: 64%, B: 7%)
31% (22/72) |
[26,27] |
|
